Levodopa motor complications in Parkinson's disease

Parkinson's disease (PD) is an age-related neurodegenerative disorder with an average onset age of 60 years. In the United States, approximately one million persons suffer from PD, and there are 60,000 newly diagnosed cases every year. The estimated cost of PD to society is $27 billion per year. Based on United States Census Bureau projections, it is estimated that the frequency of PD will increase fourfold by the year 2040, making it an even larger burden on patients, their families and society.

[1]  A. Barbeau.  Long-term side-effects of levodopa. , 1971, The Lancet.

[2]  P. Calabresi,et al.  The corticostriatal projection: from synaptic plasticity to dysfunctions of the basal ganglia , 1996, Trends in Neurosciences.

[3]  A. Benabid,et al.  Subthalamic Nucleus Deep Brain Stimulation , 2000 .

[4]  J. Obeso,et al.  Levodopa‐induced dyskinesias in Parkinson's disease: Clinical and pharmacological classification , 1992, Movement disorders : official journal of the Movement Disorder Society.

[5]  J. Nutt,et al.  Differences in the Motor Response to Apomorphine Between Untreated and Fluctuating Patients With Parkinson's Disease , 1992, Clinical neuropharmacology.

[6]  J. Obeso,et al.  Motor response to apomorphine and levodopa in asymmetric Parkinson's disease. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[7]  A. Crossman,et al.  A hypothesis on the pathophysiological mechanisms that underlie levodopa‐ or dopamine agonist‐induced dyskinesia in Parkinson's disease: Implications for future strategies in treatment , 1990, Movement disorders : official journal of the Movement Disorder Society.

[8]  A. Lang,et al.  Posteroventral medial pallidotomy in advanced Parkinson's disease. , 1997, Advances in neurology.

[9]  A. Lees,et al.  Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[10]  T. Paolo,et al.  Chronic treatment withl-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding , 1986, Brain Research.

[11]  Y. Agid,et al.  Levodopa‐induced dyskinesias in Parkinson's disease: Is sensitization reversible? , 2000 .

[12]  C. Colosimo,et al.  Motor fluctuations in Parkinson's disease: pathophysiology and treatment , 1999, European journal of neurology.

[13]  M Schulzer,et al.  Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism , 1994, Annals of neurology.

[14]  L. Schiffer,et al.  Aromatic amino acids and modification of parkinsonism. , 1967, The New England journal of medicine.

[15]  S. Fahn.  Fluctuations of disability in Parkinson's disease: pathophysiology , 1981 .

[16]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[17]  S Fahn,et al.  The spectrum of levodopa-induced dyskinesias. , 2000, Annals of neurology.

[18]  C. Marsden,et al.  Continuous dopaminergic stimulation: state of the art and outlook. , 1988, Journal of neural transmission. Supplementum.

[19]  J. Langston,et al.  Positron emission tomographic evidence for progression of human MPTP‐induced dopaminergic lesions , 1994, Annals of neurology.

[20]  O. Rascol,et al.  Continuous dopamine-receptor stimulation in early Parkinson's disease , 2000, Trends in Neurosciences.

[21]  W. Koller,et al.  An algorithm (decision tree) for the management of Parkinson's disease , 1998, Neurology.

[22]  J. Nutt,et al.  Apomorphine can sustain the long-duration response to l-DOPA in fluctuating PD , 2000, Neurology.

[23]  T. Chase,et al.  Motor fluctuations in Parkinson's disease: Pathogenetic and therapeutic studies , 1987, Annals of neurology.

[24]  J A Obeso,et al.  Motor complications associated with chronic levodopa therapy in Parkinson's disease. , 1989, Neurology.

[25]  M. Muenter,et al.  Patterns of dystonia ("I-D-I" and "D-I-D-") in response to l-dopa therapy for Parkinson's disease. , 1977, Mayo Clinic proceedings.

[26]  Hitoshi Takahashi,et al.  Endothelin‐1 in the brain of patients with galactosialidosis: Its abnormal increase and distribution pattern , 2000, Annals of neurology.

[27]  T. Engber,et al.  Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration , 1994, Brain Research.

[28]  A. Prince,et al.  HEPANOSTICON IN SCREENING FOR HBsAg , 1975, The Lancet.

[29]  N H Holford,et al.  The response to levodopa in parkinson's disease: Imposing pharmacological law and order , 1996, Annals of neurology.

[30]  J. Brotchie,et al.  Effect of Repeated l -DOPA, Bromocriptine, or Lisuride Administration on Preproenkephalin-A and Preproenkephalin-B mRNA Levels in the Striatum of the 6-Hydroxydopamine-Lesioned Rat , 1999, Experimental Neurology.

[31]  Gerfen Cr.  Dopamine-mediated gene regulation in models of Parkinson's disease. , 2000 .

[32]  J A Obeso,et al.  Preventing levodopa-induced dyskinesias. , 2000, Annals of neurology.

[33]  C. Marsden,et al.  SUCCESS AND PROBLEMS OF LONG-TERM LEVODOPA THERAPY IN PARKINSON'S DISEASE , 1977, The Lancet.

[34]  Fluctuation in response to chronic levodopa therapy: pathogenetic and therapeutic considerations. , 1987, Advances in neurology.

[35]  D. Brooks,et al.  A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. , 2000, The New England journal of medicine.

[36]  J. Parkinson.  An Essay on the Shaking Palsy , 2002 .

[37]  Niall Quinn,et al.  Young onset Parkinson's disease , 1987, Movement disorders : official journal of the Movement Disorder Society.

[38]  A. Benabid,et al.  Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. , 1998, The New England journal of medicine.

[39]  H. Ross,et al.  A 10-year study of the incidence of and factors predicting dementia in Parkinson’s disease , 2000, Neurology.

[40]  S. Kish,et al.  Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. , 1988, The New England journal of medicine.

[41]  G. Fénelon,et al.  Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. , 2000, Brain : a journal of neurology.

[42]  N. Quinn,et al.  Preservation of the substanitia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four‐year period , 1986, Movement disorders : official journal of the Movement Disorder Society.

[43]  Sandra F. Olson.  Golden Memories, Golden Opportunities , 1998, Neurology.

[44]  T. Chase,et al.  Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease , 1987, Annals of neurology.

[45]  C. Olanow.  A radical hypothesis for neurodegeneration , 1993, Trends in Neurosciences.

[46]  J. D. Parkes,et al.  Fluctuations of disability in Parkinson's disease – clinical aspects , 1981 .

[47]  J. Obeso,et al.  The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease. , 1994, The European journal of neuroscience.

[48]  Surgical therapies for Parkinson's disease. A physician's perspective. , 2001, Advances in neurology.

[49]  T. Chase,et al.  Wearing‐off fluctuations in Parkinson's disease: Contribution of postsynaptic mechanisms , 1994, Annals of neurology.

[50]  F. Grandas,et al.  Risk factors for levodopa-induced dyskinesias in Parkinson’s disease , 1999, Journal of Neurology.

[51]  J A Obeso,et al.  Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model. , 2000, Annals of neurology.

[52]  J. Langston,et al.  Pargyline prevents MPTP-induced parkinsonism in primates. , 1984, Science.

[53]  J. Hubble,et al.  Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.

[54]  J. Nutt,et al.  Effect of long-term therapy on the pharmacodynamics of levodopa. Relation to on-off phenomenon. , 1992, Archives of neurology.

[55]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[56]  Y. Agid,et al.  Levodopa‐induced dyskinesias in Parkinson's disease phenomenology and pathophysiology , 1994, Movement disorders : official journal of the Movement Disorder Society.

[57]  I. Heuser,et al.  Rationale for continuous dopaminomimetic therapy of Parkinson's disease. , 1989, Neurology.

[58]  J. Obeso,et al.  Subthalamic nucleus‐mediated excitotoxicity in parkinson's disease: A target for neuroprotection , 1998, Annals of neurology.

[59]  T. Khosla.  SUDDEN DEATH AND SPORT , 1975, The Lancet.

[60]  P. Blanchet,et al.  Molecular basis of levodopa-induced dyskinesias. , 2000, Annals of neurology.